Systematic immunohistochemical profiling of 378 brain tumors with 37 antibodies using tissue microarray technology
Systematic immunohistochemical profiling of 378 brain tumors with 37 antibodies using tissue microarray technology
复制标题
DOI：
10.1007/s00401-006-0060-1
复制
发表时间：
2006-05-01
影响因子：
12.7
通讯作者：
Nakazato, Y
中科院分区：
文献类型：
--
作者：
Ikota, H;Kinjo, S;Nakazato, Y
我们使用 37 种抗体和组织微阵列 (TMA) 技术对 378 个脑肿瘤进行了系统的免疫组织化学研究。本研究的目的是使用我们实验室建立的抗体寻找新的诊断生物标志物。我们的 TMA 由从各个供体块中提取的 1.5 毫米核心网格组成。使用三分系统对每种抗体的染色进行评分。我们使用层次聚类分析来解释这些数据，从而将所有脑肿瘤分为七组。尽管有一些例外，但具有相同组织学诊断的病例通常被分组在一起。然后我们进行了统计分析，以找到对脑肿瘤分组最有用的抗体。十种抗体 [胶质纤维酸性蛋白 (GFAP)、Olig2、波形蛋白、上皮膜抗原 (EMA)、细胞角蛋白 (AE1/AE3)、α-internexin、巢蛋白、松果体细胞 PP5、水通道蛋白 4 (AQP4) M13d 和 AQP4M13e] 可区分星形细胞瘤和少突胶质细胞瘤。六种抗体[EMA、AE1/AE3、TUJ1、巢蛋白、神经丝蛋白-MH (NF-MH) 和血管周围细胞 GP-1] 在高级别和低级别胶质瘤之间显示出显着差异。我们的数据揭示了具有潜在诊断用途的新抗体（Olig2、PP5、GP-1），并证明 TMA 技术对于评估脑肿瘤研究中新建立的抗体非常有用。
We performed a systematic immunohistochemical study on 378 brain tumors using 37 antibodies and tissue microarray (TMA) technology. The aim of this study was to find new diagnostic biomarkers using antibodies established in our laboratory. Our TMA consisted of a grid of 1.5-mm cores that were extracted from individual donor blocks. Staining for each antibody was scored using a three-point system. We used hierarchical clustering analysis to interpret these data, which resulted in separation of all the brain tumors into seven groups. Although there were some exceptions, cases with the same histological diagnosis were generally grouped together. We then carried out statistical analyses to find the most useful antibodies for grouping of brain tumors. Ten antibodies [glial fibrillary acidic protein (GFAP), Olig2, vimentin, epithelial membrane antigen (EMA), cytokeratin (AE1/AE3), alpha-internexin, nestin, pinealocytes PP5, aquaporin-4 (AQP4) M13d and AQP4M13e] discriminated between astrocytomas and oligodendroglial tumors. Six antibodies [EMA, AE1/AE3, TUJ1, nestin, neurofilament protein-MH (NF-MH) and perivascular cells GP-1] showed significant differences between high-grade and low-grade gliomas. Our data have revealed new antibodies with potential diagnostic utility (Olig2, PP5, GP-1) and demonstrate that TMA technology is highly useful for evaluating newly established antibodies in brain-tumor research.